tiprankstipranks
Stocks
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders StocksMarket MoversTipRanks 50 IndexAI StocksLargest Companies by Market Cap
ETFs
Top ETFs by UpsideTop ETFs by Smart ScoreTop Gainers/ Losers/ Active ETFs
Crypto
Bitcoin
Popular
Ethereum
Commodities
Gold
Options
Unusual Options Activity
Popular
Currency
EUR/USD
Research Tools
Trending StocksCompare StocksCompare ETFsTrump Dashboard
New
Daily Feeds
Daily Analyst RatingsDaily Insider Trading Tracker
Calendars
Earnings CalendarDividend CalendarEconomic CalendarIPO CalendarStock SplitsStock BuybacksMarket Holidays
Calculators
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Economic Indicators
Inflation RateUnemployment Rate
Class Actions
Stock ScreenerETF Screener
Popular
Penny Stock ScreenerTechnical Analysis Screener
Dividend CenterBest Dividend Stocks
Popular
Best High Yield Dividend StocksDividend AristocratsDividend Stock Comparison
New
Dividend CalculatorDividend Returns ComparisonDividend Calendar
My ExpertsTop AnalystsTop Financial BloggersTop-Performing Corporate InsidersTop Hedge Fund ManagersTop Research FirmsTop Individual Investors
Trending News
More News >
Education
Personal FinanceHow To Use TipRanksTipRanks LabsGlossaryFAQs
About Us
About TipRanksContact UsCareersReviewsMobile APP
Working with TipRanks
Enterprise SolutionsAdvertise with UsTop Online BrokersBecome an AffiliateTipRanks News Wire
Follow Us
TOOLS
Portfolio
Watchlist
Top Insiders Stocks
Popular
Top Stocks
Popular
Market Movers
Compare stocks
Compare ETFs
Notification Center
News
Stock Screener
ETF Screener
Popular
Penny Stock Screener
Technical Analysis Screener
Top Analyst Stocks
Popular
Top Smart Score Stocks
Popular
AI Analyst Top Stocks
New
Top Insiders Stocks
Compare Stocks
Compare ETFs
Trending Stocks
Daily Analyst Ratings
Daily Insiders Trades
Dividend Stocks
ETF Center
Top Gainers/losers/active ETFs
Trump Dashboard
New
Dividend Calculator
Options Profit Calculator
Dollar Cost Averaging
Compound Interest Calculator
Mortgage Calculator
Auto Loan Calculator
Student Loan Calculator
401k Retirement Calculator
Earnings Calendar
Dividend Calendar
Economic Calendar
IPO Calendar
Stock Splits
Stock Buybacks
Market Holidays
Dividend Center
Best Dividend Stocks
Popular
Best High Yield Dividend Stocks
Dividend Aristocrats
Dividend Stock Comparison
New
Dividend Calculator
Dividend Returns Comparison
Dividend Calendar
Top Analysts
Top Financial Bloggers
Top-Performing Corporate Insiders
Top Hedge Fund Managers
Top Research Firms
Top Individual Investors
Top Gainers
Top Losers
Most Active
Premarket
After-hours
Personal Finance Center
Mortgages
Loans
Investing & Retirement
Spending & Savings
Real Estate
Top Online Brokers
Enterprise Solutions
Plans & Pricing
Education
How To Use TipRanks
TipRanks Labs
Glossary
FAQs
About Us
About TipRanks
Contact Us
Careers
Reviews
Mobile APP
Working with TipRanks
Enterprise Solutions
Top Online Brokers
Become an Affiliate
TipRanks News Wire
Follow Us
STOCKS
SPY
QQQ
AAPL
NVDA
TSLA
AMZN
BABA
Advertisement
Advertisement

IRD Stock Latest News

Opus Genetics initiated with a Buy at Chardan
The FlyOpus Genetics initiated with a Buy at Chardan
4d ago
IRD
Opus Genetics’ Promising Prospects: Buy Rating Reinforced by OPGx-LCA5 Efficacy and Strategic Advancements
PremiumRatings
Opus Genetics’ Promising Prospects: Buy Rating Reinforced by OPGx-LCA5 Efficacy and Strategic Advancements
19d ago
IRD
Opus Genetics Announces Positive Phase 1/2 Trial Results
PremiumCompany Announcements
Opus Genetics Announces Positive Phase 1/2 Trial Results
20d ago
8K
IRD
Opus Genetics reports pediatric data from OPGx-LCA5 Phase 1/2 trial
PremiumThe Fly
Opus Genetics reports pediatric data from OPGx-LCA5 Phase 1/2 trial
20d ago
IRD
Opus Genetics reports inducement grant under Nasdaq listing rules
PremiumThe Fly
Opus Genetics reports inducement grant under Nasdaq listing rules
1M ago
IRD
Promising Clinical Trial Results and Safety Profile Support Buy Rating for Opus Genetics
PremiumRatingsPromising Clinical Trial Results and Safety Profile Support Buy Rating for Opus Genetics
1M ago
IRD
Opus Genetics doses first patient in LYNX-3 Phase 3 trial
Premium
The Fly
Opus Genetics doses first patient in LYNX-3 Phase 3 trial
2M ago
IRD
Opus Genetics Appoints New Chief Financial Officer
Premium
Company Announcements
Opus Genetics Appoints New Chief Financial Officer
2M ago
8K
IRD
Opus Genetics appoints Rob Gagnon as CFO
PremiumThe Fly
Opus Genetics appoints Rob Gagnon as CFO
2M ago
IRD
Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics
PremiumRatings
Promising Developments and Financial Stability Drive Buy Rating for Opus Genetics
2M ago
IRD
Opus Genetics announces FDA clearance of IND application for OPGx-BEST1
PremiumThe Fly
Opus Genetics announces FDA clearance of IND application for OPGx-BEST1
2M ago
IRD
Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating
PremiumRatings
Opus Genetics: Promising Clinical Trials and Strategic Partnerships Drive Buy Rating
2M ago
IRD
Opus Genetics reports Q2 EPS (12c) vs (30c) last year
PremiumThe FlyOpus Genetics reports Q2 EPS (12c) vs (30c) last year
2M ago
IRD
Opus Genetics Secures Funding for Gene Therapy Development
Premium
Company Announcements
Opus Genetics Secures Funding for Gene Therapy Development
3M ago
8K
IRD
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
Premium
The Fly
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
3M ago
IRD
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
PremiumThe Fly
Opus Genetics, Global RDH12 Alliance partner to advance RDH12 gene therapy
3M ago
IRD
Opus Genetics: Strategic Collaborations and Promising Trial Outcomes Justify Buy Rating
PremiumRatings
Opus Genetics: Strategic Collaborations and Promising Trial Outcomes Justify Buy Rating
4M ago
IRD
Opus Genetics: Promising Developments and Strong Pipeline Justify Buy Rating
PremiumRatings
Opus Genetics: Promising Developments and Strong Pipeline Justify Buy Rating
4M ago
IRD
Opus Genetics Announces Positive Phase 3 Trial Results
PremiumCompany Announcements
Opus Genetics Announces Positive Phase 3 Trial Results
4M ago
8K
IRD
Opus Genetics’ Phentolamine Ophthalmic Solution meets primary Phase 3 endpoint
PremiumThe FlyOpus Genetics’ Phentolamine Ophthalmic Solution meets primary Phase 3 endpoint
4M ago
IRD
Opus Genetics Secures $2M Funding for Gene Therapy
Premium
Company Announcements
Opus Genetics Secures $2M Funding for Gene Therapy
4M ago
8K
IRD
Opus Genetics awarded non-dilutive funding from the RD Fund
Premium
The Fly
Opus Genetics awarded non-dilutive funding from the RD Fund
4M ago
IRD

Trending

Name
Price
Price Change
SPX
S&P 500
DJIA
Dow Jones
NDX
Nasdaq 100
More Trending Stocks >